Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Austedo Approved to Treat Chorea in Huntington's Disease

Teva news release; 2017 Apr 3

Teva Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington's disease (HD), a rare and fatal neurodegenerative disorder. Teva Pharmaceutical Industries Ltd is headquartered in Israel.

Indications: Austedo is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of chorea associated with Huntington's disease.

Dosage/administration: The starting dose is 6 mg once daily; titrate up at weekly intervals by 6 mg per day to a tolerated dose that reduces chorea, up to a maximum recommended daily dosage of 48 mg (24 mg twice daily). Total daily dosages of ≥12 mg should be administered in 2 divided doses. Tablets should be administered with food and swallowed whole; they should not be chewed, crushed, or broken.

Adverse reactions: Most common adverse reactions were somnolence, diarrhea, dry mouth, and fatigue.

Citation:

Teva announces FDA approval of AUSTEDO™ (deutetrabenazine) tablets for the treatment of chorea associated with Huntington’s disease. [news release]. Jerusalem, Israel: Teva Pharmaceutical Industries Ltd. April 3, 2017. http://www.tevapharm.com/news/teva_announces_fda_approval_of_austedo_deutetrabenazine_tablets_for_the_treatment_of_chorea_associated_with_huntington_s_disease_04_17.aspx. Accessed April 13, 2017.

This Week's Must Reads

Tourette Syndrome, Tic Disorders, and Education, JAMA Neurology; ePub 2018 May 29; Pérez-Vigil, et al

RLS with PLMS More Common in Elderly Persons, Sleep; ePub 2018 Jun 1; Doan, Koo, Ogilvie, et al

Predicting Alpha-Synuclein Pathology Pre-Mortem, Parkinsonism Relat Disord; ePub 2018 May 17; Shprecher, et al

Excessive Daytime Sleepiness: Early Feature of DLB , Parkinsonism Relat Disord; 2018 May; Kasanuki, et al

HIV in HD Linked with Earlier Age of Symptom Onset, J Huntingtons Dis; 2018 Jun 1; Schultz, et al

Must Reads in FDA Actions

FDA Approves Medtronic’s DBS Therapy for Epilepsy, Medtronic news release; 2018 May 1

FDA Approves Expanded Use of Exparel Nerve Block, Pacira news release; 2018 Apr 6

FDA Approves Hizentra for CIDP Treatment, CSL Behring news release; 2018 Mar 16

FDA Approves Apadaz for Acute Pain Relief, KemPharm, Inc. news release; 2018 Feb 23